BOSTON–(BUSINESS WIRE)–A drug screening tool developed at Harvard T.H. Chan School of Public Health identifies a new potential anti-diabetes compound that may have applications for Alzheimer’s, other diseases.
Author: Business Wire
Bascom Palmer Researchers Discover Protein that Leads to Glaucoma
MIAMI–(BUSINESS WIRE)–A team of Bascom Palmer Eye Institute researchers has discovered that the protein cochlin is present in the eye and has an effect on glaucoma.
ACADIA Pharmaceuticals to Present at the JMP Securities Life Sciences Conference on June 24, 2015
SAN DIEGO–(BUSINESS WIRE)–ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced that it will present at the JMP Securities Life Sciences Conference on Wednesday, June 24, 2015, at 11:00 a.m. Eastern Time in New York City. A live webcast of ACADIA’s presentation will be accessible on the company’s website, www.acadia-pharm.com, under
Avenova Successfully Brings Relief to Patient with Challenging and Painful Eyelid Disease
DELRAY BEACH, Fla.–(BUSINESS WIRE)–Delray Eye Associates announced today that Delray ophthalmologist Steven I Rosenfeld, MD, FACS, who specializes in medical and surgical treatments of corneal conditions, infectious and inflammatory eye diseases, has written an article in Ophthalmic Professional describing how a new eyelid and lash hygiene product called Avenova™ successfully managed the eyelid disease of a particularly challenging patient. As Dr. Rosenfeld describes, the 68-year-old man had
ACADIA Pharmaceuticals Presents Integrated Data from Its Phase III Program with NUPLAZID™ (Pimavanserin) for Parkinson’s Disease Psychosis at the 19th International Congress of Parkinson’s Disease and Movement Disorders
SAN DIEGO–(BUSINESS WIRE)–ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced the presentation of integrated efficacy and tolerability data from its Phase III program with NUPLAZID™ (pimavanserin) at the 19th International Congress of Parkinson’s Disease and Movement Disorders held in San Diego. “Data from the integrated analysis o
Clearside Biomedical, Inc. Announces Favorable End-of-Phase 2 Review with the FDA
ALPHARETTA, Ga.–(BUSINESS WIRE)–Clearside Biomedical, Inc., a biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye, today announced a favorable End-of-Phase 2 review with the U.S. Food and Drug Admi…
Aerie Pharmaceuticals Receives Positive Feedback from FDA
IRVINE, Calif.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) (the “Company”), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, today reported that the U.S. Food and Drug Administration (FDA) has agreed in written and verbal communications that Aerie may change the primary endpoint range of its second Phase 3 registration trial of
Ocugen to Present at BIO International Convention
AURORA, Colo.–(BUSINESS WIRE)–Ocugen, Inc. today announced leadership updates and that company Chairman and CEO Dr. Shankar Musunuri will present at BIO International Convention this week in Philadelphia.
Glaukos Corporation Announces Launch of Initial Public Offering
LAGUNA HILLS, Calif.–(BUSINESS WIRE)–Glaukos Corporation, an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, announced tod…
Research and Markets: Corneal Graft Rejection – Pipeline Review, H1 2015
DUBLIN–(BUSINESS WIRE)–Research and Markets (http://www.researchandmarkets.com/research/pd5bj8/corneal_graft) has announced the addition of the “Corneal Graft Rejection – Pipeline Review, H1 2015” report to their offering. This report provides compre…
Research and Markets: Ocular Hypertension – Pipeline Review, H1 2015
DUBLIN–(BUSINESS WIRE)–Research and Markets (http://www.researchandmarkets.com/research/jrdqcj/ocular) has announced the addition of the “Ocular Hypertension – Pipeline Review, H1 2015” report to their offering. This report provides comprehensive inf…
Research and Markets: Uveitis Pipeline Review, H1 2015
DUBLIN–(BUSINESS WIRE)–Research and Markets (http://www.researchandmarkets.com/research/hw3d2f/uveitis) has announced the addition of the “Uveitis – Pipeline Review, H1 2015” report to their offering. This report provides comprehensive information on…
InSite Vision Announces Completion of the New Drug Application Submission to the U.S. FDA for BromSite
ALAMEDA, Calif.–(BUSINESS WIRE)–InSite Vision Incorporated (OTCBB:INSV) today announced that it has completed the submission to the U.S. Food and Drug Administration (FDA) of the New Drug Application (NDA) of BromSite™ for the treatment of inflammation and prevention of pain in cataract surgery. InSite is seeking marketing approval of BromSite in the United States. In its confirmatory Phase 3 clinical trials, BromSite achieved statistically significant superiority to vehicle in alleviating oc
LENSAR erhält CE-Kennzeichnung für fünf neue Leistungsanwendungsupgrades am LENSAR-Lasersystem
ORLANDO, Florida (USA)–(BUSINESS WIRE)–LENSAR Inc., ein globaler Führer in der Femtosekunden-Lasertechnologie für refraktive Kataraktchirurgie, hat heute mitgeteilt, dass es für eine Suite aus fünf neuen Anwendungstechnologien, die in das Vorzeigeprodukt des Unternehmens, das LENSAR® Laser System, integriert wurden, die CE-Kennzeichnung der Regulierungsbehörde der Europäischen Union erhalten hat. Als erste Femtosekunden-Laserkataraktplattform zur Ermöglichung der Automatisierung von Planungs-
LENSAR obtient le marquage CE pour cinq nouvelles mises à niveau d’application de performance du système laser LENSAR
ORLANDO, Floride–(BUSINESS WIRE)–LENSAR, Inc., un leader mondial en technologie laser femtoseconde de prochaine génération pour la chirurgie de la cataracte réfractive, a annoncé aujourd’hui que les régulateurs de l’Union européenne lui avaient accordé le marquage CE pour une série de cinq nouvelles technologies d’application intégrées au produit phare de la société, le système laser LENSAR®. En tant que première plateforme de cataracte laser femtoseconde à permettre l’automatisation des élém
Samenvatting: LENSAR krijgt CE-markering voor vijf upgrades van LENSAR Laser System
ORLANDO, Fla.–(BUSINESS WIRE)–LENSAR Inc., wereldleider in femtosecondelasertechnologie voor de operatie van hardnekkige grijze staar, heeft vandaag bekendgemaakt dat het een CE-markering heeft gekregen van de Europese Unie voor een reeks van vijf to…
Resumen: LENSAR recibe marcado CE para cinco nuevas actualizaciones de las prestaciones de las aplicaciones para el sistema láser LENSAR
ORLANDO, Fla.–(BUSINESS WIRE)–LENSAR, Inc., líder mundial en tecnología láser femtosegundo de próxima generación para la cirugía refractiva de cataratas, ha anunciado hoy que ha recibido el marcado CE de los organismos de la Unión Europea para una gama de cinco nuevas tecnologías de aplicaciones en el producto insignia de la compañía, el sistema láser LENSAR®. El comunicado en el idioma original, es la versión oficial y autorizada del mismo. La traducción es solamente un medio de ayuda y debe
FDA Awards Isarna Orphan Drug Designation for ISTH0036 to Improve Glaucoma Treatment Outcome
MUNICH–(BUSINESS WIRE)–Isarna Therapeutics adds FDA orphan drug designation to its ISTH0036 program to treat prevention of scarring post glaucoma filtration surgery.
LENSAR Receives CE Mark for Five New Performance Application Upgrades to the LENSAR Laser System
ORLANDO, Fla.–(BUSINESS WIRE)–LENSAR, Inc., announces receipt of the CE Mark for five application upgrades to the LENSAR® Laser System with Streamline™ for femtosecond cataract surgery.
Riassunto: LENSAR riceve il marchio CE per cinque nuovi aggiornamenti alle prestazioni dell’applicazione per il sistema laser LENSAR
ORLANDO, Florida–(BUSINESS WIRE)–LENSAR, Inc., leader a livello mondiale della tecnologia laser a femtosecondi di nuova generazione per la chirurgia refrattiva per cataratta, ha annunciato oggi di aver ricevuto il marchio CE da parte degli enti regolatori dell’Unione Europea per un pacchetto di cinque nuove tecnologie di applicazione integrate nel prodotto fiore all’occhiello della società, il sistema laser LENSAR®. Il testo originale del presente annuncio, redatto nella lingua di partenza, è